500 ITP patients under the microscope: what real clinics reveal about treatment
NCT ID NCT07268898
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will review medical records of 500 people with newly diagnosed or persistent immune thrombocytopenia (ITP) across multiple hospitals in China. Researchers will look at what treatments patients actually received and how well they worked, without influencing their care. The goal is to map the current treatment landscape and identify patterns that could guide better management of ITP.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors understand which treatments work best for ITP in everyday practice, potentially improving care guidelines.
- What could go wrong
- This is an observational study that only looks back at existing records, so it cannot prove cause and effect. Results may not apply to all patients or regions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA (ITP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an RNA 'Message' reprogram the immune system to stop autoimmune blood disorders?
- Can a bispecific antibody tame two autoimmune blood disorders?
- Can a gut bacteria transplant help when steroids fail for a bleeding disorder?
- Will a new drug form work the same? study tests two versions of SKI-O-703
- New drug mimics IVIg to fight low platelet disorder
- New drug combo aims to tame stubborn blood disorders